Figure 3 from Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

Elacestrant therapy duration and OS by prior fulvestrant exposure. Depicted are clinical outcomes on elacestrant therapy comparing patients with versus those without previous treatment with fulvestrant. Patients treated with fulvestrant before elacestrant are displayed in red, and those without prior fulvestrant are displayed in blue. A depicts the TTNT, B depicts the TTD, and C depicts the OS. The adjusted HR and corresponding 95% CI comparing the two groups are displayed. Vertical hash marks denote a censored patient event. CL, confidence limit.